Just got a reply from paul5 Oct 2021 16:12
Thank you for your email.
Abingdon Health already announced in the 12 August 2021 update that it is ". working on the transfer of two COVID-19 antigen tests to manufacture."
One of those two tests is the Vatic test, referred to in the weekend media. This tech transfer process is still in progress and not yet complete, but once that is complete and the company has received purchase orders for tests to be manufactured (and therefore has an idea of how many tests will be required to be made) then this does become meaningful to shareholders and is something to be announced.
Also, once this test is launched by Vatic, should demand for the produce become such that ABDX receives significant levels of purchase orders then this may change the Company's view on performance or expected performance and so a further announcement would be required. None of this is known at the moment. So for now, the Company has updated shareholders that they are working on the transfer of two COVID-19 antigen tests and when these complete they would look to update shareholders further.
Kind regards,
Paul
Paul McManus
Managing Director